Wyeth BMP-2 Panel Review Signals “Not Approvable” Issues Are Resolved
This article was originally published in The Gray Sheet
Executive Summary
Wyeth is reinterpreting clinical data from a 450-patient pivotal study supporting a BMP-2 premarket approval application